Bavelloni, A. et al. 2017. PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma. Italian Journal of Anatomy and Embryology. 122, 1 (Oct. 2017), 21.